A Nonfucosylated Variant of the anti-HIV-1 Monoclonal Antibody b12 Has Enhanced Fcγ/RIIIa-Mediated Antiviral Activity In Vitro but Does Not Improve Protection against Mucosal SHIV Challenge in MacaquesMOLDT, Brian; SHIBATA-KOYAMA, Mami; DUGAST, Anne-Sophie et al.Journal of virology. 2012, Vol 86, Num 11, pp 6189-6196, issn 0022-538X, 8 p.Article

Complement-mediated tumor-specific cell lysis by antibody combinations targeting epidermal growth factor receptor (EGFR) and its variant III (EGFRvIII)KLAUSZ, Katja; BERGER, Sven; LAMMERTS VAN BUEREN, Jeroen J et al.Cancer science. 2011, Vol 102, Num 10, pp 1761-1768, issn 1347-9032, 8 p.Article

Targeting interleukin-15 in patients with rheumatoid arthritis : A proof-of-concept studyBASLUND, Bo; TVEDE, Niels; PARREN, Paul W. H. I et al.Arthritis and rheumatism. 2005, Vol 52, Num 9, pp 2686-2692, issn 0004-3591, 7 p.Article

An Antibody-Drug Conjugate That Targets Tissue Factor Exhibits Potent Therapeutic Activity against a Broad Range of Solid TumorsBREIJ, Esther C. W; DE GOEIJ, Bart E. C. G; PARREN, Paul W. H. I et al.Cancer research (Chicago, Ill.). 2014, Vol 74, Num 4, pp 1214-1226, issn 0008-5472, 13 p.Article

Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCCREPP, Roland; KELLNER, Christian; VAN DE WINKEL, Jan G. J et al.Journal of immunological methods. 2011, Vol 373, Num 1-2, pp 67-78, issn 0022-1759, 12 p.Article

HuMab-7D8, a monoclonal antibody directed against the membrane-proximal small loop epitope of CD20 can effectively eliminate CD20^low expressing tumor cells that resist rituximab-mediated lysisVAN MEERTEN, Tom; ROZEMULLER, Henk; MARTENS, Anton C et al.Haematologica (Roma). 2010, Vol 95, Num 12, pp 2063-2071, issn 0390-6078, 9 p.Article

Rapid Production of Recombinant Human IgG With Improved ADCC Effector Function in a Transient Expression SystemVAN BERKEL, Patrick H. C; GERRITSEN, Jolanda; VAN VOSKUILEN, Edwin et al.Biotechnology and bioengineering. 2010, Vol 105, Num 2, pp 350-357, issn 0006-3592, 8 p.Article

Fc receptor but not complement binding is important in antibody protection against HIVHESSELL, Ann J; HANGARTNER, Lars; MARX, Preston A et al.Nature (London). 2007, Vol 448, Num 7158, pp 101-104, issn 0028-0836, 4 p.Article

Effect of target dynamics on pharmacokinetics of a novel therapeutic antibody against the epidermal growth factor receptor : Implications for the mechanisms of actionLAMMERTS VAN BUEREN, Jeroen J; BLEEKER, Wim K; BOGH, Henrik O et al.Cancer research (Baltimore). 2006, Vol 66, Num 15, pp 7630-7638, issn 0008-5472, 9 p.Article

Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumabVAN DER VEER, Michael S; DE WEERS, Michel; VAN KESSEL, Berris et al.Haematologica (Roma). 2011, Vol 96, Num 2, pp 284-290, issn 0390-6078, 7 p.Article

The in vivo mechanism of action of CD20 monoclonal antibodies depends on local tumor burdenBOROSS, Peter; MARCO JANSEN, J. H; LEUSEN, Jeanette H. W et al.Haematologica (Roma). 2011, Vol 96, Num 12, pp 1822-1830, issn 0390-6078, 9 p.Article

Estimation of dose requirements for sustained in vivo activity of a therapeutic human anti-CD20 antibodyBLEEKER, Wim K; MUNK, Martin E; MACKUS, Wendy J. M et al.British journal of haematology. 2008, Vol 140, Num 3, pp 303-312, issn 0007-1048, 10 p.Article

A human CD4 monoclonal antibody for the treatment of T-cell lymphoma combines inhibition of T-cell signaling by a dual mechanism with potent Fc-dependent effector activityRIDER, David A; HAVENITH, Carin E. G; CAMBIER, John et al.Cancer research (Baltimore). 2007, Vol 67, Num 20, pp 9945-9953, issn 0008-5472, 9 p.Article

Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomasTEELING, Jessica L; FRENCH, Ruth R; VALERIUS, Thomas et al.Blood. 2004, Vol 104, Num 6, pp 1793-1800, issn 0006-4971, 8 p.Article